Skip to main content

Table 4 Diagnostic results for primary analyses, rows bolded passed four validity diagnostics

From: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade®

Study pop.

Database

Target

Comparator

T events

C events

0 event Pass

Max ASD

ASD Pass

Equipoise

Equipoise Pass

EASE

EASE Pass

Total Passed

AS

Amb EMR

Remicade®

AS comparator

0

0

0

0.302

0

0.531

1

0.976

0

1

AS

Pharmetrics

Remicade®

AS comparator

6

9

1

0.157

0

0.405

1

0.044

1

3

AS

Optum® EHR

Remicade®

AS comparator

< 5

6

1

0.218

0

0.638

1

0.233

1

3

AS

Clinformatics®

Remicade®

AS comparator

< 5

< 5

1

0.272

0

0.417

1

0.172

1

3

AS

CCAE

Remicade®

AS comparator

< 5

6

1

0.239

0

0.434

1

0.180

1

3

IBD

Amb EMR

Remicade®

IBD comparator

< 5

< 5

1

0.09

1

0.422

1

0.284

0

3

IBD

Pharmetrics

Remicade®

IBD comparator

12

42

1

0.047

1

0.431

1

0.074

1

4

IBD

Optum® EHR

Remicade®

IBD comparator

< 5

7

1

0.055

1

0.480

1

0.087

1

4

IBD

Clinformatics®

Remicade®

IBD comparator

6

15

1

0.105

0

0.412

1

0.040

1

3

IBD

CCAE

Remicade®

IBD comparator

10

18

1

0.071

1

0.387

1

0.107

1

4

PsO/PsA

Amb EMR

Remicade®

PsO/PsA comparator

0

0

0

0.145

0

0.254

0

0.344

0

0

PsO/PsA

Pharmetrics

Remicade®

PsO/PsA comparator

< 5

10

1

0.132

0

0.155

0

0.178

1

2

PsO/PsA

Optum® EHR

Remicade®

PsO/PsA comparator

6

< 5

1

0.099

1

0.306

0

0.246

1

3

PsO/PsA

Clinformatics®

Remicade®

PsO/PsA comparator

0

7

0

0.199

0

0.171

0

0.110

1

1

PsO/PsA

CCAE

Remicade®

PsO/PsA comparator

< 5

9

1

0.167

0

0.147

0

0.010

1

2

RA

Amb EMR

Remicade®(m)

RA comparator

< 5

0

0

0.127

0

0.445

1

0.307

0

1

RA

Pharmetrics

Remicade®(m)

RA comparator

< 5

6

1

0.179

0

0.352

1

0.158

1

3

RA

Optum® EHR

Remicade®(m)

RA comparator

5

< 5

1

0.097

1

0.558

1

0.141

1

4

RA

Clinformatics®

Remicade®(m)

RA comparator

< 5

8

1

0.252

0

0.363

1

0.034

1

3

RA

CCAE

Remicade®(m)

RA comparator

< 5

8

1

0.151

0

0.508

1

0.070

1

3

  1. Key: <5 = a censored value between 1 and 4; Amb EMR = IQVIA Ambulatory Electronic Medical Records; AS comparator = certolizumab pegol, golimumab, ixekizumab, or secukinumab; AS = ankylosing spondylitis; ASD = absolute standardized difference; CCAE = Merative™ MarketScan® Commercial Database; Clinformatics® = Optum® De-Identified Clinformatics® Data Mart Database; EASE = expected absolute systematic error; IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); Optum® EHR = Optum® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; PsO/PsA comparator = golimumab, certolizumab pegol, guselkumab, risankizumab, tildrakizumab, brodalumab, ixekizumab, secukinumab, or ustekinumab; PsO/PsA = psoriatic conditions plaque psoriasis or psoriatic arthritis; RA comparator = certolizumab pegol or tocilizumab; RA = rheumatoid arthritis; Remicade®(m) = Remicade® exposure with concurrent methotrexate; Study pop. = study population
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us